JPWO2022025150A1 - - Google Patents
Info
- Publication number
- JPWO2022025150A1 JPWO2022025150A1 JP2022539547A JP2022539547A JPWO2022025150A1 JP WO2022025150 A1 JPWO2022025150 A1 JP WO2022025150A1 JP 2022539547 A JP2022539547 A JP 2022539547A JP 2022539547 A JP2022539547 A JP 2022539547A JP WO2022025150 A1 JPWO2022025150 A1 JP WO2022025150A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020130935 | 2020-07-31 | ||
| JP2020130935 | 2020-07-31 | ||
| JP2020163258 | 2020-09-29 | ||
| JP2020163258 | 2020-09-29 | ||
| PCT/JP2021/028008 WO2022025150A1 (ja) | 2020-07-31 | 2021-07-29 | 乳がん治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022025150A1 true JPWO2022025150A1 (https=) | 2022-02-03 |
| JP7792336B2 JP7792336B2 (ja) | 2025-12-25 |
Family
ID=80035757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539547A Active JP7792336B2 (ja) | 2020-07-31 | 2021-07-29 | 乳がん治療剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230172924A1 (https=) |
| EP (1) | EP4151212A4 (https=) |
| JP (1) | JP7792336B2 (https=) |
| KR (1) | KR20230047056A (https=) |
| CN (1) | CN115996722A (https=) |
| AU (1) | AU2021315234A1 (https=) |
| BR (1) | BR112022027069A2 (https=) |
| CA (1) | CA3185174A1 (https=) |
| MX (1) | MX2023000060A (https=) |
| TW (1) | TW202220652A (https=) |
| WO (1) | WO2022025150A1 (https=) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505562A (ja) * | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| WO2017104739A1 (ja) * | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
| WO2021210636A1 (ja) * | 2020-04-17 | 2021-10-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094812A1 (es) * | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| JP2014235614A (ja) | 2013-06-03 | 2014-12-15 | 株式会社ゼネット | 総合学習支援ネットワークシステム及び総合学習支援方法 |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| JP2017217935A (ja) | 2016-06-03 | 2017-12-14 | 株式会社東海理化電機製作所 | ステアリングスイッチ装置 |
| JP2018022750A (ja) | 2016-08-02 | 2018-02-08 | 太陽誘電株式会社 | 積層セラミックコンデンサ |
| US11219619B2 (en) * | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
-
2021
- 2021-07-29 AU AU2021315234A patent/AU2021315234A1/en active Pending
- 2021-07-29 US US18/008,304 patent/US20230172924A1/en active Pending
- 2021-07-29 CA CA3185174A patent/CA3185174A1/en active Pending
- 2021-07-29 MX MX2023000060A patent/MX2023000060A/es unknown
- 2021-07-29 TW TW110127880A patent/TW202220652A/zh unknown
- 2021-07-29 WO PCT/JP2021/028008 patent/WO2022025150A1/ja not_active Ceased
- 2021-07-29 BR BR112022027069A patent/BR112022027069A2/pt unknown
- 2021-07-29 EP EP21850938.8A patent/EP4151212A4/en active Pending
- 2021-07-29 CN CN202180045666.7A patent/CN115996722A/zh active Pending
- 2021-07-29 JP JP2022539547A patent/JP7792336B2/ja active Active
- 2021-07-29 KR KR1020227045161A patent/KR20230047056A/ko active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505562A (ja) * | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| WO2017104739A1 (ja) * | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
| WO2021210636A1 (ja) * | 2020-04-17 | 2021-10-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
Non-Patent Citations (6)
| Title |
|---|
| BREAST CANCER RESEARCH, vol. 19, JPN6021033465, 2017, pages 1 - 14, ISSN: 0005619110 * |
| BREAST CANCER RESEARCH, vol. 21, JPN6021033467, 2019, pages 1 - 14, ISSN: 0005619112 * |
| CLINICAL CANCER RESEARCH, vol. 23, no. 20, JPN6021033466, 2017, pages 6138 - 6150, ISSN: 0005619111 * |
| MOLECULAR CANCER THERAPEUTICS, vol. 15, no. 11, JPN6021033461, 2016, pages 2630 - 2639, ISSN: 0005619108 * |
| NATURE REVIEWS CLINICAL ONCOLOGY, vol. 16, no. 2, JPN6021033464, 2019, pages 105 - 122, ISSN: 0005619109 * |
| SECKL, MICHAEL ET AL.: "RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.35, No.15, Supplement 1, JPN7021003397, 2017, ISSN: 0005619113 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220652A (zh) | 2022-06-01 |
| JP7792336B2 (ja) | 2025-12-25 |
| US20230172924A1 (en) | 2023-06-08 |
| BR112022027069A2 (pt) | 2023-02-07 |
| AU2021315234A1 (en) | 2023-01-19 |
| MX2023000060A (es) | 2023-02-01 |
| CA3185174A1 (en) | 2022-02-03 |
| EP4151212A1 (en) | 2023-03-22 |
| KR20230047056A (ko) | 2023-04-06 |
| EP4151212A4 (en) | 2024-04-10 |
| WO2022025150A1 (ja) | 2022-02-03 |
| CN115996722A (zh) | 2023-04-21 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251014 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251215 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7792336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |